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Objective. To assess the therapeutic potential of a
P2X purinergic receptor antagonist, namely, periodate
oxidized ATP, in collagen-induced arthritis (CIA).
Methods. Arthritis was induced in male DBA/1J
mice by immunization with type II collagen (CII).
Animals showing digit inflammation and paw swelling
were treated intraperitoneally with 100 l of 3 mM
oxidized ATP daily for 10 days. At the end of the
treatment period, animals were killed and paws were
removed for histologic analysis and evaluation of T cell
infiltration. Humoral response to CII was analyzed, and
specific serum autoantibody levels were correlated with
the clinical scores observed in the different treatment
groups.
Results. Treatment with oxidized ATP resulted in
a sustained reduction in disease activity, which was
associated with a significant decrease in CD3 T cell
infiltration in arthritic lesions and a significant amelio-
ration of cartilage erosion. Peripheral Treg cells were
significantly increased upon P2X blockade in mouse
lymph nodes. Moreover, a marked reduction in circu-
lating autoantibodies directed against mouse CII was
detected. There was a significant correlation between
serum autoantibody levels and the clinical efficacy of
oxidized ATP.
Conclusion. Our findings indicate that P2X re-
ceptor antagonism has important therapeutic potential
in chronic inflammatory rheumatic disorders. Taken
together, our results underscore the value of the P2X
receptor signaling pathway as a potential pharmaco-
logic target for the modulation of adaptive immunity
in CIA.
Rheumatoid arthritis (RA) is a chronic inflam-
matory disease that primarily affects the joints, causing
pain, stiffness, and synovitis and leading to articular
destruction. The etiology of RA is multifactorial,
with genetic and environmental components that de-
termine early immune perturbation in both the innate
and adaptive compartments and subsequent chronic
inflammation (1). The molecular and cellular patho-
genic mechanisms that cause RA and/or determine the
chronic nature of the disease are poorly understood. In
RA, the synovial tissue of the periarticular spaces is
infiltrated by granulocytes and a large number of mono-
nuclear cells, including T cells, B cells, monocytes, and
macrophages (2).
Immunization of DBA/1J mice with type II col-
lagen (CII) results in a break in tolerance and genera-
tion of CII-specific T cells and anti-CII autoantibodies,
with clinical signs that mimick RA (collagen-induced
arthritis [CIA] model). In spite of the detection of CII-
specific T cells in arthritic joints, passive transfer of
CII-specific T cells to susceptible mouse strains induces
only minor pathologic changes in the synovial joints of
recipients (3). In contrast, consistent with the impor-
tance of autoantibodies in the immunopathogenesis of
Supported in part by Merck Serono SA. The study was
conducted at the Merck Serono Institute of Biomedical Research
Antoine Marxer RBM facility through a research agreement between
Gaslini Hospital and Merck Serono SA.
1Vittoria Ardissone, PhD: Merck Serono SA RBM SpA
Istituto di Ricerche Biomediche Antoine Marxer, Turin, Italy, and
IRCCS G. Gaslini, Genoa, Italy (current address: Procelltech, Turin,
Italy); 2Enrico Radaelli, DVM, PhD, Dipl ECVP: Fondazione Filerete
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CIA, passive transfer of anti-CII sera from arthritic mice
to naive recipients induces severe inflammation even in
nonsusceptible strains (4). A defect in peripheral toler-
ance has been observed in RA patients as well as in
animal models of RA. Several studies have indicated
that quantitative and qualitative abnormalities of Treg
cells contribute to the pathogenesis of CIA and RA (5).
Indeed, Treg cells can actively modulate the auto-
immune response in inflammatory arthritis (6).
Two major classes of molecules interacting with
cellular receptors have been defined as major determi-
nants of innate and adaptive immune system activation
in chronic inflammatory and autoimmune conditions,
namely, pathogen-associated molecular patterns and
damage-associated molecular patterns (DAMPs) (7).
Among the latter, extracellular ATP, which is massively
released upon cell death, plays a crucial role in promot-
ing a number of inflammatory immune responses.
Plasma membrane receptors for extracellular ATP,
termed P2 receptors, are found on virtually all cell types.
They are divided into 2 families: P2X receptors, which
are ATP-gated nonselective cation channels, and P2Y
receptors, which are heterotrimeric G protein–coupled
receptors. ATP was shown to crucially contribute to
inflammasome activation through P2X7 activation in
cells of the innate immune system. Notably, deletion of
P2X7 receptor attenuates the inflammatory response in
a passive model of antibody-induced arthritis (8).
In addition to the well-documented role of ATP
as a DAMP for cells of the innate immune system,
recent studies have demonstrated that ATP is also
critically involved in determining productive T cell acti-
vation. Indeed, ATP is released by CD4 T cells upon
stimulation with cognate antigen, and consequent auto-
crine P2X receptor stimulation plays a crucial role in
protracting T cell receptor (TCR)–initiated MAPK in-
duction (9,10). Moreover, P2X antagonism was shown to
blunt MAPK activation without affecting NF-AT nu-
clear translocation, thus determining T cell unrespon-
siveness to subsequent stimulation (anergy) (9). Finally,
the activation of P2X7 by ATP inhibits the suppressive
potential of Treg cells, and pharmacologic antagonism
of P2X receptors promotes conversion of naive CD4
T cells into Treg cells after TCR stimulation (11). These
observations suggest that ATP acts as a soluble factor
regulating Treg cell immunosuppressive potential and
de novo generation.
In the present study, we investigated the role of
oxidized ATP as a P2X receptor antagonist in the
treatment of CIA. We demonstrated a dramatic amelio-
ration of symptoms, an increase in peripheral Treg cells,
and a significant reduction in circulating anti-CII auto-
antibodies. These findings suggest the potential applica-
tion of this class of therapeutics to modulation of the
autoimmune response in RA patients.
MATERIALS AND METHODS
Induction and treatment of CIA. All animal studies
were approved by the authorized veterinarian and were autho-
rized by the Italian Ministry of Health (decree no. 124/2007-
B). CIA was induced and evaluated as previously described
(12). Briefly, 8-week-old male DBA/1J mice (Charles River
Japan) were immunized on day 0 with an intradermal injection
into the base of the tail of 0.2 ml of an emulsion containing 2
mg/ml of bovine CII (Morwell Diagnostics) in Freund’s com-
plete adjuvant (CFA; Difco) containing 2 mg/ml of Mycobac-
terium tuberculosis. Immunization with CFA and CII resulted,
after 18–20 days, in the appearance of signs of inflammation
affecting 1 or more limbs. When animals showed visible clinical
signs (digit inflammation and paw swelling) resulting in a
clinical score of 1.5, treatment was started. Mice were treated
with intraperitoneal injections of either phosphate buffered
saline (PBS; 100 l) or oxidized ATP (3 mM in 100 l of PBS)
(Sigma-Aldrich) daily for 10 consecutive days. At the end of
the treatment period, animals were killed with an overdose of
anesthetic. Blood samples were collected from each animal,
and paws were removed for histologic analysis. Plasma anti-CII
antibody titers were determined by enzyme-linked immunosor-
bent assay (ELISA), according to the recommendations of the
manufacturer (Morwell Diagnostics).
Flow cytometric analysis. Mouse spleens and
mesenteric/inguinal lymph nodes were harvested and smashed
through a cell strainer; after erythrocyte lysis, cells were
stained with CD11b and Gr-1 antibodies (Becton Dickinson)
and analyzed by flow cytometry using a FACSCalibur instru-
ment (Becton Dickinson). For flow cytometric analyses, mono-
clonal antibodies conjugated with either biotin, fluorescein
isothiocyanate, phycoerythrin, CyChrome, PerCP, or allo-
phycocyanin against the following antigens were used: CD8a
(53-6.7), CD4 (L3T4), CD62L (MEL-14), CD44 (IM7), CD19
(6D5), CD21 (8D9), CD23 (B3B4) (all from eBioscience), IgM
(II/41), IgD (11.26c.2a), and FoxP3 (MF23) (all from BD
Biosciences). Data were analyzed with CellQuest Pro software
(Becton Dickinson).
Evaluation of interleukin-10 (IL-10) production. An in
vitro IL-10 secretion assay was performed as follows. Briefly,
CD19 B cells were isolated from mouse spleens by immuno-
magnetic beads and stimulated for 5 hours with lipopolysac-
charide (LPS; 10 g/ml), phorbol myristate acetate (1 g/ml),
and ionomycin (1 g/ml). Intracellular staining with anti–IL-10
antibodies was performed. IL-10 production was also evalu-
ated by ELISA in supernatants of CD19 B cells stimulated
for 4 days with CpG 1826 (2.5 g/ml).
Histologic analysis. For histologic analysis, in each
animal, the first limb to become arthritic was identified,
removed, fixed in 10% neutral buffered formalin, and decal-
cified in formic acid solution (50%). The paw was then
embedded in paraffin, and 2 sagittal sections were prepared.
Tissue sections were stained with hematoxylin and eosin or
Safranin O and scored as previously described (12).
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Immunohistochemical analysis. For immunohisto-
chemistry, serial formalin-fixed and paraffin-embedded sections
from each animal were immunostained with primary anti-
bodies raised against CD3, complement C3c fraction, mouse
IgG, and FoxP3. Dako EnVision polymer was used to detect
the immunoperoxidase reaction. Immunoreactivity was re-
vealed by incubating the sections with 3,3-diaminobenzidine
(Vector). Sections were counterstained with Mayer’s hema-
toxylin. For each sample, serial sections were also incubated
with rabbit polyclonal anti–Helicobacter pylori antibodies
(Dako) as a negative control. To establish the extent of CD3
T cell infiltration in mouse arthritic lesions, each sample was
scanned at 40 magnification, and 3 immunoreactive areas
were selected from within articular/periarticular inflammatory
lesions. Upon identification of these areas, the number of
immunopositive cells with membranous CD3 expression
was further defined at 200 magnification. To establish the
extent of FoxP3 Treg cells populating the arthritic lesions,
synovial membranes and articular capsules present in each
sample were scanned at 100 magnification for the identifica-
tion of 6 immunoreactive foci. Upon identification of these
foci, the number of immunopositive cells with FoxP3 nuclear
expression was further defined at 200 magnification.
Statistical analysis. Clinical score variances were ana-
lyzed using two-way analysis of variance (ANOVA) followed
by Bonferroni adjustment. Cartilage erosion was analyzed by
Mann-Whitney test. One-way ANOVA followed by Tukey’s
test was used to analyze secondary lymphoid organ cellularity
and granulocyte representation. Serum IgG autoantibody con-
centration was analyzed by Student’s t-test.
RESULTS
In order to test whether pharmacologic P2X
receptor antagonism affected arthritis development in
Figure 1. A, Left, Clinical scores for male DBA/1J mice with collagen-induced arthritis (CIA) treated with either phosphate buffered saline (PBS)
(open symbols; n  12) or oxidized ATP (3 mM) (solid symbols; n  13) intraperitoneally. Treatment was started when clinical signs of arthritis
were present (clinical score 1.5). The clinical score variation was calculated for each day, using as a reference the clinical score observed before
the first administration of treatment. Values are the mean  SEM of 2 independent experiments.   P  0.01;   P  0.001 versus PBS
treatment, by two-way analysis of variance followed by Bonferroni adjustment. Middle, Time-integrated area under the curve (AUC) clinical score
variations for the treatment period (days 1–10) calculated versus the first day of treatment (day 1) (solid bar) and for the recovery period (days
10–17) calculated versus the last day of treatment (day 10) (open bar). Right, Cartilage erosion. Sections from mice with CIA treated with PBS
(solid bar; n  4) or oxidized ATP (open bar; n  6), were stained with Safranin O, and cartilage erosion was evaluated in a blinded manner. Bars
show the mean  SEM.   P  0.03 versus PBS treatment, by Mann-Whitney test. B–D, Histologic features of sections from a healthy control
mouse (B), a mouse with CIA treated with PBS (C), and a mouse with CIA treated with oxidized ATP (D). Arrows indicate healthy cartilage.
Original magnification  50.
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DBA/1J mice, 10 daily injections of oxidized ATP (100 l
of 3 mM solution) were administered intraperitoneally
starting when the animals began to show clinical signs of
disease and had a clinical score of 1.5. The treatment
was well tolerated, and no systemic toxicity was observed
(data not shown). Treatment with oxidized ATP resulted
in a significant reduction in the clinical score, which
measured inflammation of the digits and paw swelling
(Figure 1A). A reduction in the clinical score for oxi-
dized ATP–treated mice compared to that for PBS-
treated mice was already evident after the first injection,
and this reduction reached statistical significance in
the second half of the treatment period. On day 10, the
treatment was stopped, and a group of animals was
followed up for 7 days to assess whether the ameliorative
effect of oxidized ATP was maintained after treatment
suspension. The significant reduction in clinical score
observed at the end of the experimental period versus
treatment initiation was maintained during this recovery
period; variations in clinical score were unchanged
(Figure 1A).
At the end of the treatment period (day 10),
animals were killed and paws were removed for histo-
logic analysis. P2X blockade induced a significant re-
duction in cartilage erosion, evaluated as proteoglycan
content (Figure 1A). Notably, in mice treated with
oxidized ATP, cartilage surfaces were structurally con-
served compared to mice treated with PBS, which
showed massive cellular infiltration and cartilage profile
damage (Figures 1B–D).
In response to collagen immunization, higher
numbers of cells were recovered from the spleens and
draining inguinal lymph nodes of immunized compared
to nonimmunized mice (Figure 2A). This cellular expan-
sion was decreased in mice treated with oxidized ATP;
the decrease was statistically significant in lymph nodes
Figure 2. A, Total number of mononuclear cells in the spleens (left panel) and lymph nodes (middle panel) and number of
CD11bhighGr-1 spleen cells (right panel) in mice without CIA (naive), mice with CIA treated with PBS, and mice with CIA
treated with oxidized ATP (oATP).   P  0.01;   P  0.001, by one-way analysis of variance followed by Tukey’s test.
B, Absolute number of CD4CD25highFoxP3 CD4 T cells in the spleens and lymph nodes of mice with CIA treated with PBS
(open bars) or oxidized ATP (solid bars), enumerated by intracellular staining.   P  0.0407 by t-test. C, Results of reverse
transcriptase–polymerase chain reaction analysis showing an abundance of FoxP3 transcripts in CD4 T cells isolated from the
lymph nodes of animals injected with PBS or oxidized ATP. Bars show the mean  SEM. See Figure 1 for other definitions.
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Figure 3. Absolute numbers of CD4 and CD8 T cells and of the CD4 and CD8 cell subsets CD44CD62L (naive),
CD44CD62L (effector memory [EM]), and CD44CD62L (central memory [CM]) in the spleens (A) and lymph nodes
(LNs) (B) of mice with CIA treated with PBS (open bars) or oxidized ATP (solid bars). Bars show the mean  SEM. See Figure
1 for other definitions.
Figure 4. A, Absolute numbers of CD3 cells in specimens from mice with CIA treated with PBS (solid bar) or oxidized ATP
(oATP; open bar) (left panel), determined by CD3 immunostaining of formalin-fixed and paraffin-embedded acral portions
of limbs from mice with CIA treated with PBS (middle panel) or oxidized ATP (right panel). Bars show the mean  SEM.
  P  0.05 versus PBS treatment, by one-way analysis of variance followed by Tukey’s test. Original magnification  40.
B, Number of FoxP3 cells relative to the total number of CD3 cells infiltrating the joints in mice with CIA treated with PBS
or oxidized ATP. For each slide, the synovial membrane and articular capsule were scanned at 100 magnification for
identification of 6 immunoreactive foci. The number of FoxP3 cells was defined at 200 magnification. Bars show the mean 
SEM. See Figure 1 for other definitions.
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(Figure 2A). A feature of T cell–mediated immunopa-
thology is the increase in immature and mature elements
of the granulocyte lineage in the spleen due to enhanced
granulopoiesis in the bone marrow, which is induced by
inflammation mediators (13). Treatment with oxidized
ATP resulted in a significant reduction in CD11bhigh
Gr-1high mature granulocytes in the mouse spleen, thus
suggesting the amelioration of this inflammation-related
feature (Figure 2A).
No differences in the numbers of naive, effector
memory, or central memory CD4 or CD8 T cells
were observed in mice treated with oxidized ATP com-
pared to mice treated with PBS (Figure 3). Also,
cytokine-secreting cells were not affected by P2X block-
ade (data not shown). Nonetheless, we observed a sig-
nificant increase in the absolute numbers of CD4
CD25highFoxP3 Treg cells in the spleens as well as
lymph nodes of mice treated with oxidized ATP com-
pared to mice treated with PBS (Figure 2B). This
observation was confirmed by real-time reverse
transcriptase–polymerase chain reaction analysis show-
ing an abundance of FoxP3 messenger RNA in CD4 T
cells isolated from mice treated with oxidized ATP
compared to control mice injected with PBS. FoxP3
expression was significantly increased in CD4 T cells
upon P2X blockade in vivo, thus suggesting that the
immunoregulatory suppressive function of Treg cells
was initiated by oxidized ATP (Figure 2C).
To establish the extent of T cell infiltration in
arthritic lesions, formalin-fixed and paraffin-embedded
sections from mice treated with oxidized ATP or PBS
were immunostained with CD3-specific antibody, and
Figure 5. A–D, Percentages and absolute numbers of CD19 B lymphocytes in the spleens and lymph nodes (LNs) (A), of mature (IgMIgD)
B cells in the lymph nodes (B), of marginal zone (MZ; CD19CD21CD23) and follicular (FO; CD19CD21CD23) B cells in the
spleens (C), and of germinal center (FasGL7) B cells in the spleens and lymph nodes (D) of mice with CIA treated with PBS (open bars)
or oxidized ATP (oATP; solid bars). E, Ex vivo analysis of interleukin-10 (IL-10)–secreting B cells from mice with CIA treated with PBS
(open bars) or oxidized ATP (solid bars). Bars show the mean  SEM. See Figure 1 for other definitions.
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each sample was scanned at 40 magnification; 3 im-
munoreactive hot spots were selected from within the
articular/periarticular inflammatory lesions. For each
hot spot, the number of CD3 lymphocytes was
counted. Oxidized ATP induced a significant decrease
in CD3 T cells infiltrating the synovial tissue of the
periarticular space (Figure 4A). Since the frequency of
Treg cells relative to conventional T cells is an impor-
tant parameter for effective immunosuppression, we
determined the number of FoxP3 Treg cells in inflam-
matory lesions by staining with an anti-FoxP3 antibody.
Interestingly, the ratio of Treg cells to total CD3 was
increased by oxidized ATP, suggesting the development
of more effective tissue-specific immunosuppression by
P2X antagonism (Figure 4B).
The humoral autoimmune response has patho-
genic relevance in the model of CIA used in this study
(14). Thus, we evaluated the effect of P2X signaling
blockade on the composition of mature B cell subsets.
The representation of marginal zone B cells (CD19
CD21CD23) and follicular B cells (CD19CD21
CD23) in the mouse spleen was not modified by
treatment with oxidized ATP (Figure 5C). Accordingly,
mature B cells in the lymph nodes analyzed as CD19
Figure 6. A, Levels of circulating anti–mouse type II collagen (CII) antibodies in mice with CIA treated with PBS (solid bar)
or oxidized ATP (open bar), determined by enzyme-linked immunosorbent assay (for total IgG). After treatment with either
PBS (n  8) or oxidized ATP (n  8), mice were killed, blood was collected, and concentrations of anti–mouse CII IgG were
determined.   P  0.05 versus PBS treatment, by Student’s t-test. B, Correlation between cumulative clinical score at the end
of the treatment period and anti–mouse CII antibody titer in mice with CIA treated with oxidized ATP (n  11) (F  17.52;
df numerator, df denominator  1.000, 9.000; P  0.0024). C, Absorbance for IgG subclass antibodies and IgA and IgM
antibodies specific for mouse CII in mice treated with PBS (open bars) or oxidized ATP (solid bars). Sera were diluted 1:500.
Bars in A and C show the mean  SEM.   P  0.04, by Student’s t-test. OD  optical density (see Figure 1 for other
definitions).
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IgMIgD were not altered in oxidized ATP–treated
mice compared to PBS-treated control mice (Figure 5B).
Notably, we observed a slight, although not significant,
difference in the percentages of germinal center B cells
(CD19GL7Fas) in the spleens and lymph nodes of
oxidized ATP–treated mice (Figure 5D).
Recent studies have shown that B cells can
participate in peripheral immunoregulation through
the secretion of IL-10 upon Toll-like receptor (TLR)
stimulation (15). These cells were shown to interfere
with the development of several autoimmune diseases,
including experimental autoimmune encephalomyelitis
and CIA. Thus, we analyzed the frequency of IL-10–
secreting B cells in the spleens and lymph nodes of
animals treated with oxidized ATP. Intracellular cyto-
kine staining was performed after B cell stimulation with
LPS, phorbol myristate acetate, and ionomycin in vitro
for 5 hours. No differences in the percentages or abso-
lute numbers of IL-10–secreting B cells were observed
upon P2X blockade (Figure 5E). We quantitatively
evaluated IL-10 secretion by B cells stimulated with
CpG 1826, a TLR-9 agonist and potent inducer of IL-10
secretion by B cells (15). CD19 B cells were stimulated
with CpG 1826 (2.5 g/ml) in vitro for 4 days, and IL-10
secretion was measured in the culture supernatant by
ELISA. B cells isolated from mice treated with oxidized
ATP secreted a similar amount of IL-10 as B cells from
control mice treated with PBS, further supporting the
notion of a lack of induction of IL-10–secreting B cells
by oxidized ATP (Figure 5E).
We next evaluated total serum IgG specific for
bovine and mouse CII by ELISA. Treatment with oxi-
dized ATP significantly reduced serum concentrations of
IgG autoantibodies specific for CII (Figure 6A), while
levels of anti–bovine CII antibodies were not affected
(data not shown). We also analyzed the IgG subclass
antibodies and IgA and IgM antibodies specific for
mouse CII. Only specific antibodies of the IgG1 isotype
were significantly diminished by oxidized ATP, whereas
specific antibodies of the IgG2a, IgG2b, IgG3, IgA, and
IgM isotypes were unaltered (Figure 6C). Notably, a
significant correlation between serum IgG autoantibody
concentrations and clinical outcome was observed, indi-
cating that the reduced severity of the disease was
associated with a decrease in circulating IgG autoanti-
body levels (Figure 6B).
DISCUSSION
TCR stimulation results in an early increase in
ATP synthesis and release, which acts as a crucial
autocrine costimulus in CD4 T helper cell activation
(9,10). Inhibition of purinergic P2X signaling results in
diminished T cell proliferation and induction of a tran-
scription program, which leads to T cell unresponsive-
ness to subsequent stimulation (anergy). In addition,
purinergic P2X7 antagonism results in more stable ex-
pression of FoxP3 in immunosuppressive Treg cells and
facilitates de novo generation of adaptive Treg cells in
the periphery (11). Taken together, these observations
suggest that purinergic P2X antagonism might be useful
in specific down-regulation of adaptive immune re-
sponses. Indeed, treatment of murine inflammatory
bowel disease (IBD) and type 1 diabetes mellitus (DM)
with oxidized ATP dramatically ameliorated the out-
comes of these diseases (9). In the present study, we
showed that therapeutic administration of oxidized ATP
as a P2X antagonist was also effective in the treatment
of CIA, an animal model of RA, in which B cells and
innate immune system cells are more readily involved in
disease pathogenesis than in IBD and type 1 DM.
With regard to histopathologic parameters, mice
treated with oxidized ATP in the present study had
lower synovial inflammation and cartilage erosion scores
than mice treated with PBS. This observation is consis-
tent with the results of a previous study, which showed
that P2X7-deficient mice had milder arthritis after they
received anticollagen antibodies (8). Given that T cell
infiltration plays an essential role in the pathogenesis of
CIA (11), we evaluated T cell content in the arthritic
joints of the mice. We found fewer CD3 T cells and an
increased Treg cell:total CD3 cell ratio in joints from
oxidized ATP–treated mice compared to PBS-treated
mice, further supporting the notion of a crucial role of
effector T cells in sustaining joint inflammation in CIA.
Nonetheless, the beneficial effect of oxidized ATP in
inflamed joints could also be related to a direct effect of
the drug on synoviocytes. Indeed, the latter are involved
in joint injury by producing inflammatory cytokines such
as IL-6, and it has been demonstrated that human syno-
viocytes isolated from RA patients express functional
P2X7, whose activation promotes IL-6 secretion (16).
As a general consequence of immunization with
adjuvants (17), as well as during chronic inflammation
(13), hematopoiesis in the bone marrow is skewed
toward granulopoiesis, and mature granulocytes are
increased in the spleen. Analogously, under conditions
of peripheral T cell–mediated immunopathology, ma-
ture and immature granulocytes are detected in the
spleen (13). Treatment with oxidized ATP resulted in a
reduction in the percentage of splenic mature granulo-
cytes, showing that purinergic P2X antagonism might
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modulate this effector mechanism of T cell–mediated
immunopathology. The activation and function of neu-
trophils were recently shown to be controlled by an
autocrine loop of ATP and purinergic signaling; there-
fore, P2X antagonism by oxidized ATP in CIA could
also exert a direct effect on granulocytes.
CIA, the most commonly used model for studying
antirheumatic drugs, reproduces many of the pathogenic
mechanisms detected in human RA, including increased
cellular infiltration, synovial hyperplasia, pannus forma-
tion, and erosion of cartilage and bone in the distal joints
(3). Participation of T and B cells is required to initiate
the disease, and their relative contribution needs to be
further clarified. Germinal centers are found in a signif-
icant proportion of RA synovia, and high autoantibody
titers indicate a poor prognosis of the disease (2).
In the present study, we showed that treatment
with oxidized ATP resulted in a significant decrease in
collagen-specific IgG autoantibodies. Notably, collagen-
specific IgG levels correlated with the clinical scores of
mice treated with oxidized ATP, suggesting a direct
involvement of B cells as autoreactive plasma cells in
the pathogenesis of CIA. It remains to be elucidated
whether the effect reported on serum antibody levels is
due to a direct effect of oxidized ATP on B cells or to a
limited availability of T cell help. P2X7 expression has
been described in the human B cell line (18), and the
role of B cells in CIA pathogenesis has already been
hypothesized. The MT/ mice, which lack B cells due
to the disruption of the  heavy chain transmembrane
exon, are resistant to CIA induction (19). Furthermore,
transfer of immune sera from arthritic mice induces
severe inflammation (4). Finally, as proof of principle of
the pathogenetic role of B cells in RA, treatment with
rituximab, a chimeric B cell–depleting anti-CD20 anti-
body, has demonstrated that the depletion of B cells can
substantially improve signs and symptoms as well as
physical function in RA patients whose disease is not
responsive to tumor necrosis factor –blocking agents
(20). Therefore, it can be assumed that B cells, as
antibody-producing as well as antigen-presenting and
cytokine-secreting cells, represent major contributors to
RA pathogenesis.
In conclusion, we have shown that pharmacologic
inhibition of P2X signaling can effectively ameliorate
CIA by inhibiting peripheral inflammatory tissue de-
struction and the autoreactive humoral response. This
effect was associated with the expansion of tissue-
specific Treg cells. Therefore, pharmacologic targeting
of the P2X signaling pathway may dampen excessive
inflammation and cure inflammatory autoimmune dis-
eases such as RA.
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